- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03678194
Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application (SMART)
Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In industrialized countries, depression is the leading cause of disability with a cumulative DALY (disability adjusted life years) that his greater than all the other psychiatric or medical conditions (WHO, 2004). Although the medical treatment is efficient for a large number of patients, two major pitfalls can be highlighted: i). the difficulty to identify and alter risk factors related to therapeutic observance; and ii). the heterogeneous presentation of depression, which may require specific interventions depending on the clinical presentation of the patient.
Ecological Momentary Assessment (EMA; also referred to as the Experience Sampling Method) is a method used to gather and interpret real-time data collected in the contexts of daily life through mobile technologies (Stone 1994). It has been used extensively in the field of psychiatry and specifically in mood disorders and it has been shown to be both feasible for patients with depression (Husky 2010, Swendsen 2012) and effective in identifying determinants of mood fluctuations and medication observance (Myin Germeys 2003, Ebner-Primer 2009, Solhan 2009, Silk 2011, Wichers 2010, Rot 2012, Armey 2015, Wenze 2010, Armey 2015). The restitution of the data to patients also has an important added benefit in terms of prognosis, as patients are better integrated in their own care (Wichers 2011, Kramer 2014).
Although EMA has been shown to offer promising advantages, it has also been limited by the technical solutions used to gather information on daily life experiences. Rather than using research-dedicated devices which represent the majority of existing tools, the development of an application-based solution could revolutionize the field by creating the first effective and widely-diffusable tool to help clinicians better manage depression with the collaboration of their patients. This application would be designed to help patients monitor their symptoms, while providing regular interventions to increase medication.
This is a randomized study in two groups to test and validate an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.
In this multicentric study, 200 patients with a DSM-V diagnosis of depression are recruited.
Participants will be assessed by:
- Hetero-evaluations: diagnostic (MINI), depressive symptomatology (HDRS), clinical impression (CGI).
- Auto-evaluations: depressive symptomatology (BDI), medication adherence (MARS), Quality of Life (Q-LES-Q-SF), therapeutic alliance (4PAS).
Two groups will be formed by randomization (100 per groups):
- Groupe SMART: smartphone (experimental group). This group will performed all clinical evaluations and will download the study application on their smartphone to answer daily questionnaires about symptom severity, medication adherence, during 6 weeks. Participants will be given a smartphone, if the subject does not have one. Clinical visits with psychiatrist will be performed every two weeks, with questionnaires to fill.
- Groupe TAU: Treatment as Usual (control group). This group will performed all clinical evaluations and have the same follow-up as the intervention group, but without smartphone application.
Expected results Patient benefit: The principle expected benefit for patients concerns their more active participation in their own health care, in the philosophy that the better they understand their disorder and the triggers of symptom expression, the better than can intervene to improve their mental health.
Clinician benefit: It can provide high resolution data of depressive symptoms, therapeutic adherence and symptoms fluctuations on his patients, to better follow the remission or to adjust treatment daily dose.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David MISDRAHI, M.D
- Phone Number: +33(0)556563449
- Email: dmisdrahi@ch-perrens.fr
Study Locations
-
-
-
Bordeaux, France, 33076
- Recruiting
- Centre Hospitalier Charles Perrens
-
Contact:
- David MISDRAHI, M.D
- Phone Number: 003356563449
- Email: dmisdrahi@ch-perrens.fr
-
Contact:
- Helen SAVARIEAU, MSc
- Phone Number: 003356563556
- Email: hsavarieau@ch-perrens.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 65 years;
- Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;
- Patients started their antidepressant treatment less than 5 days before inclusion;
- Patient treated in an outpatient setting;
- Patient informed of the diagnosis of his disease;
- Informed patient with written consent.
Exclusion Criteria:
- A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;
- A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;
- Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;
- Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);
- Non-comprehension of the French language
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Smartphone application
This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up).
The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
|
6 weeks smartphone application with daily evaluations
|
No Intervention: Standard services
This group of patients receives conventional treatment only.
Clinical evaluations are provided at the same endpoint.
Patients still receive standard services for depression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A greater clinical response in the active group (smartphone application) comparatively to the comparator group (clinical response was defined as a decline in HDRS-17 score greater than 50%)
Time Frame: Baseline (pre-treatment). 8 weeks post-baseline
|
HDRS Hamilton Depressive Rating Scale.
Changes in HDRS scores of at least 50% at 8 weeks.
|
Baseline (pre-treatment). 8 weeks post-baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in scores for therapeutic alliance
Time Frame: baseline (pre-treatment). 8 weeks post-baseline
|
Measurement by the 4PAS (4-Point Ordinal Alliance Self-Report)
|
baseline (pre-treatment). 8 weeks post-baseline
|
Improvement in scores for medication adherence
Time Frame: 8 weeks after enrollment
|
Measurement by the MARS (Medical Adherence Rating Scale)
|
8 weeks after enrollment
|
Improvement in scores for Quality of Life
Time Frame: 8 weeks after enrollment
|
Measurement by the Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form)
|
8 weeks after enrollment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018 A01465-50
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Smartphone Support System
-
Carnegie Mellon UniversityCompletedDietary Habits | Compliance BehaviorUnited States
-
Dr. Behcet Uz Children's HospitalNot yet recruiting
-
Ming-Chyi HuangUnknown
-
Seoul National University HospitalAjou University School of Medicine; Soonchunhyang University Hospital; Saint... and other collaboratorsCompletedOut-of-Hospital Cardiac ArrestKorea, Republic of
-
University of FloridaNational Institutes of Health (NIH); International Centre for Diarrhoeal Disease... and other collaboratorsCompleted
-
Stockholm UniversityCompletedPhobic Disorders | Panic DisorderSweden
-
Wings Health AGUniversity Hospital, Basel, SwitzerlandRecruitingProstate Cancer | Psychosocial StressorSwitzerland
-
Chestnut Health SystemsRecruitingSubstance Use DisordersUnited States
-
Population Health Research InstituteUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Childhood Obesity Foundation and other collaboratorsActive, not recruiting
-
University College DublinCompleted